drugset / Trial / NCT04319783
Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA
Phase 2
Active not recruiting
65 enrolled
Trans Tasman Radiation Oncology Group
Bayer · collabPeter MacCallum Cancer Centre, Australia · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Darolutamide is a drug that has a proven survival benefit in non-metastatic (M0) castrate resistant prostate cancer when using conventional imaging. However, it is estimated that \>90% of patients have disease apparent when using PSMA PET. This study investigates the use of local consolidation radiotherapy in this cohort of men.
Timeline
- Start
- 2021-06-02
- Primary completion
- 2026-06
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Darolutamide | Other / unclassified | 600 mg | — |